Children's Oncology Group's 2013 blueprint for research: neuroblastoma. - Wikidata - wikimedia - TriplyDB

Children's Oncology Group's 2013 blueprint for research: neuroblastoma.

Children's Oncology Group's 2013 blueprint for research: neuroblastoma.

http://www.wikidata.org/entity/Q38068818

about

Pediatric genitourinary oncology Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.Aurora kinases as targets in drug-resistant neuroblastoma cells Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology.Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation.Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.Outcome for children with metastatic solid tumors over the last four decades A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies.Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance.Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database.MicroRNAs define distinct human neuroblastoma cell phenotypes and regulate their differentiation and tumorigenicity Genome-wide microarray expression and genomic alterations by array-CGH analysis in neuroblastoma stem-like cells.Neuroblastoma: molecular pathogenesis and therapy.A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma Inhibition of Neuroblastoma Tumor Growth by Ketogenic Diet and/or Calorie Restriction in a CD1-Nu Mouse Model.Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma.ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib N-linked glycan profiling in neuroblastoma cell lines.NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis The role of formyl peptide receptor 1 (FPR1) in neuroblastoma tumorigenesis.Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma.Molecular profiling of childhood cancer: Biomarkers and novel therapies Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.Combination of metronomic cyclophosphamide and dietary intervention inhibits neuroblastoma growth in a CD1-nu mouse model.Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction.The mTOR signaling pathway in pediatric neuroblastoma.The roles of microRNAs in neuroblastoma.Percutaneous transhepatic biliary drainage in an infant with obstructive jaundice caused by neuroblastoma.Targeted molecular radiotherapy of pediatric solid tumors using a radioiodinated alkyl-phospholipid ether analog.Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.Racotumomab for treating lung cancer and pediatric refractory malignancies.ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance miR-362-5p inhibits proliferation and migration of neuroblastoma cells by targeting phosphatidylinositol 3-kinase-C2β.Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status.

P2860

Q27007650-724BE75C-5109-41BB-9E70-DFD8048800D4 Q27853373-6E11498E-7240-46B9-A595-24A86E217541 Q28543446-804C8D53-FBDF-4052-A0F7-6859501F8D3F Q30239861-9FD82FDA-BC1E-44D4-A7EE-13E277B39E48 Q31095310-41E24F95-7673-4B31-8A06-B989ACBF9F49 Q33568776-C872EA76-5BA8-4A2D-83EF-BC4F34B854B2 Q33659849-3628BBEB-5E22-4A0D-9BC0-0143A08EFB9C Q33863587-D84DB930-C503-4F68-A08E-069E47745461 Q34484061-B3A22F85-1658-4166-B111-2A9D35566232 Q34953372-CF4BA9A6-E454-47E4-866C-51DE064032D4 Q35097218-7882AAFF-3A80-4741-9DC1-C3278EEF36D1 Q35129132-3ADEAE2E-980E-4300-8F82-A601C37830FC Q35178612-4E89B2F4-4B3A-4B15-A5C5-FAECBFB4E56A Q35416653-9DF48089-308E-4334-907A-5A2FF6C49CA3 Q35564199-BCD4E7AD-DB0A-4EC3-B826-F177B6A19052 Q35644191-8A531AC3-0FB2-4D72-912A-1E9D64EF2F31 Q35656317-2210F2F0-1398-4957-973E-2C2222121165 Q35755392-D035A5E3-E727-4424-B41B-CE7AF4F3EACE Q35790720-281C70D2-1DE1-4D12-B008-05FC444B4149 Q35892304-580E77C8-36D0-42C2-8729-1C3A8B4A2F8B Q36022258-C3F470CF-02AE-4FB8-8935-247ADF40EDE1 Q36081204-577644A9-5C05-470E-B7CA-F53E667FB9CF Q36212750-AE42F60B-E463-47ED-979E-854D77DAB637 Q36250783-23E72248-0120-42BD-8D7E-688D8306396A Q36278738-7A0E9D32-DD23-49A8-AAFD-63F9AD42F8BC Q36641925-86F3D776-3B72-4EB7-9DFA-3A85E43219B4 Q36739006-00DB5562-74F8-4333-B7F1-4C4255E5F579 Q36772203-A7CEFA99-2433-45BB-B5B2-966A4FE20820 Q37086200-85978A13-D8A5-49DF-B8D1-D9230079A433 Q37153180-6CFB3BB0-1986-4BDF-A4A9-A6F1399E3552 Q38108676-58E70667-B9E5-4F7D-89A6-97E65D3670C9 Q38182012-B3E2BF6F-3E05-4F1A-AFD4-625AC9AAE4C3 Q38304664-5CEBCBFF-1198-4814-AF37-746893B4F114 Q38659292-BD54E056-2F5D-47D1-9B5B-F561FEDC9DC5 Q38684328-0912DE63-DBFD-459C-8BE2-F84B10B4A598 Q38741378-B1D1F574-2069-4E04-807A-86BAD2EB1AF9 Q38745411-4B35FCDC-A83B-4B0B-AC37-01BCB669013E Q38752310-20C743D1-C640-4355-9775-12D33BBA2C5D Q38864216-982070FC-3616-4562-9DF5-566292842CD1 Q38902467-C8677D18-BB0B-4F2A-8E48-B63714BC92E0

P2860

Children's Oncology Group's 2013 blueprint for research: neuroblastoma.

http://www.wikidata.org/entity/Q38068818

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Children's Oncology Group's 2013 blueprint for research: neuroblastoma.

@en

type

label

Children's Oncology Group's 2013 blueprint for research: neuroblastoma.

@en

prefLabel

Children's Oncology Group's 2013 blueprint for research: neuroblastoma.

@en

P1433

Q38068818-54EA072B-CE1D-475B-AB6A-1F3417483A34

P1476

Q38068818-A2CE8BA2-415A-40B0-A18B-B08E0BC5FFC6

P2093

Q38068818-099B1ED7-94B5-47B7-87FB-C1FEAF7A1DAC

Q38068818-75F84829-A94B-44E2-B648-7EB042B6254F

Q38068818-92F12B75-FB5E-45BA-B788-2B1A0CA916EF

Q38068818-AC3C109D-2CEE-4402-A860-321BC39F09CA

Q38068818-BACF1176-3C88-477C-857D-4CF1D3C65856

Q38068818-C368D782-409C-4CDE-8A8E-5EFE0EC30FA5

Q38068818-EBFA7CB1-E8C7-4EF3-B996-D55F50CA96EB

P2860

Q38068818-06581B74-4F56-4565-A7E4-7F3EE611AC86

Q38068818-0D24E03F-FF93-4280-A892-7B3BE0730786

Q38068818-120A3B49-6B24-4827-BDEE-F8D14D7339BD

Q38068818-1510C064-0988-41F4-9319-A4DEA0D9F23F

Q38068818-178B9A39-264A-4CDB-9DE9-0C53905392A9

Q38068818-19B81C8D-E0D4-46AC-96FC-E4177798C97A

Q38068818-1B0C3C0F-58AA-4C4E-90EE-9EB2760D592F

Q38068818-1BC2E313-1544-495B-B989-3DA83F8C2CA9

Q38068818-1C3B84EA-3523-436D-B114-D01AAA626EB4

Q38068818-1FEF9DAC-0121-4A05-AA3C-BBC91C5BBEA6

P304

Q38068818-05CB0BB9-66AF-44ED-A30A-F7AA7B88D966

P31

Q38068818-5F5315E3-F36A-4DDA-8194-B7E87683FAF1

P356

Q38068818-5D9AF45F-87ED-437F-9FAB-4BCFA0D65976

P433

Q38068818-2D694FD8-6D77-47EC-B60C-43E671E04BFB

P478

Q38068818-C39F2912-C337-422D-98A2-29737BCF983C

P50

Q38068818-92F1EA38-B5A8-47A5-8A64-A5AF26D7D890

P577

Q38068818-D6D41A99-3302-485E-96D8-FAE3CF9823A3

P698

Q38068818-CC77BD00-DF2D-4109-842B-CC2C83183A77

P356

P1433

Pediatric Blood & Cancer

P1476

Children's Oncology Group's 2013 blueprint for research: neuroblastoma.

@en

P2093

COG Neuroblastoma Committee

http://www.w3.org/2001/XMLSchema#string

John M Maris

http://www.w3.org/2001/XMLSchema#string

Julie R Park

http://www.w3.org/2001/XMLSchema#string

Katherine K Mattay

http://www.w3.org/2001/XMLSchema#string

Michael Hogarty

http://www.w3.org/2001/XMLSchema#string

Rochelle Bagatell

http://www.w3.org/2001/XMLSchema#string

Wendy B London

http://www.w3.org/2001/XMLSchema#string

P2860

Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Outcome after reduced chemotherapy for intermediate-risk neuroblastoma

Copy number variation at 1q21.1 associated with neuroblastoma

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma

Identification of ALK as a major familial neuroblastoma predisposition gene

Chromosome 6p22 locus associated with clinically aggressive neuroblastoma

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage

P304

985-993

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.24433

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23255319

http://www.w3.org/2001/XMLSchema#string